论文部分内容阅读
目的探讨原发性小肠弥漫性大B细胞淋巴瘤(DLBCLs)的临床病理特征、CD10表达与患者预后的关系。方法回顾性分析24例原发性小肠DLBCLs的临床和病理资料,全部患者均经Ann Arbor分期,采用免疫组化法检测手术标本。结果Ⅰ和Ⅱ期患者15例(62.5%),Ⅲ和Ⅳ期9例(37.5%),Karnofsky状态分析平均为75.5%(40%～100%)。24例患者中,20例(83.30%)行手术治疗,16例(66.7%)接受化疗,无放射治疗患者。在19例采用免疫组化检测的患者中,CD10阳性7例(36.8%),CD10阳性组与CD10阴性组的治疗结果比较,差异无统计学意义(P=0.28),但CD10阳性表达更多在Ⅰ期患者中(P=0.013)。19例患者获随访,平均生存期32.7个月(1～111个月),5例(26.3%)死亡。统计分析显示,Ⅰ、Ⅱ期患者与Ⅲ、Ⅳ期患者的生存率差异有统计学意义(P= 0.0197),而CD10阳性组与CD10阴性组比较,差异无统计学意义。结论原发性小肠DLBCLs中,Ⅰ、Ⅱ期患者的预后(包括手术和化疗)比Ⅲ、Ⅳ期更好,CD10阳性更多的表达在Ⅰ期淋巴瘤患者中。
Objective To investigate the clinicopathological characteristics of primary small intestinal diffuse large B cell lymphoma (DLBCLs) and the relationship between the expression of CD10 and the prognosis of patients. Methods The clinical and pathological data of 24 cases of DLBCLs in primary small intestine were retrospectively analyzed. All the patients were staged by Ann Arbor, and the specimens were examined by immunohistochemistry. Results Fifty-one patients (62.5%) were in stage I and II, 9 (37.5%) in stage III and IV, and 75.5% (40% -100%) in Karnofsky status analysis. Of the 24 patients, 20 (83.30%) were treated surgically and 16 (66.7%) received chemotherapy without radiation. Among the 19 patients tested by immunohistochemistry, CD10 was positive in 7 cases (36.8%). There was no significant difference between CD10 positive group and CD10 negative group (P = 0.28), but CD10 positive expression was more In stage I patients (P = 0.013). Twenty-nine patients were followed up with an average survival of 32.7 months (range, 1 to 111 months) and five patients (26.3%) died. Statistical analysis showed that there was significant difference in the survival rates between stage Ⅰ and stage Ⅱ patients and stage Ⅲ and stage Ⅳ patients (P = 0.0197), while there was no significant difference between CD10 positive group and CD10 negative group. Conclusion The prognosis (including surgery and chemotherapy) of patients with stage Ⅰ and Ⅱ of primary small intestine DLBCLs is better than that of stage Ⅲ and Ⅳ, and CD10 is more positive in patients with stage Ⅰ lymphoma.